1. Effect of a hydrophilic and a hydrophobic statin on cardiac salvage after ST-elevated acute myocardial infarction - a pilot study
- Author
-
Tadasuke Chitose, Hideki Shimomura, Jun Hokamaki, Kenji Sakamoto, Seigo Sugiyama, Yasuyuki Yamashita, Shinya Shiraishi, Takuro Yamashita, Hisao Ogawa, and Ryusuke Tsunoda
- Subjects
Male ,Ubiquinone ,Atorvastatin ,Myocardial Infarction ,Pilot Projects ,Natriuretic Peptide, Brain ,Myocardial infarction ,Prospective Studies ,Rosuvastatin Calcium ,Thallium ,Sulfonamides ,Ejection fraction ,biology ,Fatty Acids ,Heart ,Middle Aged ,Echocardiography ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,Hydrophobic and Hydrophilic Interactions ,medicine.drug ,medicine.medical_specialty ,Acute coronary syndrome ,Statin ,medicine.drug_class ,Reperfusion therapy ,Internal medicine ,medicine ,Humans ,Rosuvastatin ,Pyrroles ,cardiovascular diseases ,Radionuclide Imaging ,Aged ,Tomography, Emission-Computed, Single-Photon ,business.industry ,Iodobenzenes ,Myocardium ,nutritional and metabolic diseases ,Cholesterol, LDL ,medicine.disease ,Fluorobenzenes ,Pyrimidines ,Heptanoic Acids ,biology.protein ,Creatine kinase ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business - Abstract
Early statin therapy after acute coronary syndrome reduces atherothrombotic vascular events. This study aimed to compare the effects of hydrophilic and hydrophobic statins on myocardial salvage and left ventricular (LV) function in patients with ST-elevated myocardial infarction (STEMI).Seventy-five STEMI patients who had received emergency reperfusion therapy were enrolled and randomized into the hydrophilic statin group (rosuvastatin; 5 mg/day, n = 38) and hydrophobic statin group (atorvastatin; 10 mg/day, n = 37) for 6 months. LV ejection fraction (LVEF), and B-type natriuretic peptide (BNP) and co-enzyme Q10 (CoQ10) levels were measured at baseline and the end of treatment. The myocardial salvage index was assessed by single photon emission computed tomography with (123-)I-β-methyl-iodophenylpentadecanoic acid (ischemic area-at-risk at onset of STEMI: AAR) and (201-)thallium scintigraphy (area-at-infarction at 6 months: AAI) [myocardial salvage index = (AAR-AAI) × 100/AAR (%)].Onset-to-balloon time and maximum creatine phosphokinase levels were comparable between the groups. After 6 months, rosuvastatin (-37.6% ± 17.2%) and atorvastatin (-32.4% ± 22.4%) equally reduced low-density lipoprotein-cholesterol (LDL-C) levels (p = 0.28). However, rosuvastatin (+3.1% ± 5.9%, p0.05), but not atorvastatin (+1.6% ± 5.7%, p = 0.15), improved LVEF. Rosuvastatin reduced BNP levels compared with atorvastatin (-53.3% ± 48.8% versus -13.8% ± 82.9%, p0.05). The myocardial salvage index was significantly higher in the rosuvastatin group than the atorvastatin group (78.6% ± 29.1% versus 52.5% ± 38.0%, p0.05). CoQ10/LDL-C levels at 6 months were increased in the rosuvastatin group (+23.5%, p0.01) and percent changes in CoQ10/LDL-C were correlated with the myocardial salvage index (r = 0.56, p0.01).Rosuvastatin shows better beneficial effects on myocardial salvage than atorvastatin in STEMI patients, including long-term cardiac function, associated with increasing CoQ10/LDL-C.URL http://www.umin.ac.jp/ctr/index.htm Unique Identifier: UMIN000003893.
- Published
- 2014